JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Anrukinzumab is a humanized monoclonal antibody that binds to IL-13 and inhibits attachment of IL-13 to IL-4Rα, thus interrupting IL-13 signaling. It was developed for the treatment of asthma and ulcerative colitis.